Immune checkpoint inhibitors

Durvalumab and Pabolizumab for lung cancer treatment

Durvalumab and Pabolizumab for lung cancer treatment

Small cell lung cancer (SCLC) is a rapidly developing, invasive lung cancer that accounts for about 15% of all lung cancer cases. Among them, about three-quarters of patients with small […]

Immune Checkpoint Inhibitors in Older Adults

Immune Checkpoint Inhibitors in Older Adults

Cancer is primarily a disease of the older adult with more than 50 % of new cases occurring in adults older than 65 years. The care of older adults with cancer can […]

Immune checkpoint inhibitors: a new frontier in bladder cancer

Immune checkpoint inhibitors: a new frontier in bladder cancer

  Immunotherapy and immune checkpoint inhibition in particular present an exciting opportunity for the treatment of bladder cancer. Over the last 30 years, bladder cancer patients have seen few advances in the […]

Immune checkpoint inhibitors: a patent review(2010-2015)

Immune checkpoint inhibitors: a patent review(2010-2015)

The ability of the immune system to detect and eliminate cancer was first proposed over 100 years ago. Since then, T cells reactive against tumor-associated antigens have been detected in […]